Psychedelic medicine (I'm not kidding, it's an emerging branch. I talked about it here) takes steps forward. The startup Ei Ventures has developed a transdermal patch for sustained-release delivery of psilocin, the active ingredient in psilocybin mushrooms, otherwise known as “magic mushrooms,” for medicinal purposes.
Psilocybin is a naturally produced psychedelic compound from more than 200 species of mushrooms. When consumed, the drug produces mind-altering effects, such as hallucinations and feelings of euphoria. Current legislation on the medicinal and recreational use of psilocybin varies from country to country, but strong pressure from academia, as well as the medical community, sees this natural drug as a possible therapeutic medicine.
Psilocybin: the rescue of magic mushrooms
With more studies examining these compounds as possible treatments for mood disorders like depression, anxiety, and addiction, psilocybin and other psychedelic drugs have recently experimented a scientific renaissance.
Very promising data from early-stage clinical trials suggests that psilocybin can effectively treat several serious mental health problems. These include major depressive disorder, alcohol dependence, obsessive-compulsive disorder, generalized anxiety, PTSD and more. Side effects from psilocybin are milder, and while further testing is needed, initial results suggest that serious side effects are rare.
David Nikzad, CEO of Ei-Ventures
Will the “psychedelic patch” become a drug?
We must be clear that psilocybin is not free from harm risks. Risks that obviously are greater in recreational settings than in medical ones. The right dosage and the right controlled environment, however, could exploit the positive aspects of the substance while reducing the risks.
When the FDA (which is now testing the compound) approves psilocybin, it will need to be distributed into the bloodstream consistently, in small amounts and for a long time. For this Nikzad and other experts point to the transdermal patch.
Transdermal administration offers a potentially higher dosage curve and better tolerability.
David Nikzad, CEO of Ei-Ventures
Compared to simply ingesting psilocybin, a patch allows for direct absorption into the bloodstream and the ability to meet dose delivery.
Psilocybin in patches: why it can work
In theory, a patch is much safer and more effective. When you ingest a drug, the dosage reaches the peak of its effectiveness and then begins to decline as the body breaks it down. A patch, on the other hand, is able to regulate the administration of dosages over a longer period, without peaks and maintaining the desired efficacy threshold until the contents of the patch are exhausted.
Not only that: all a user needs to do to stop delivery with a patch is remove it, while ingested products require the user to wait for the effects.
Despite a great deal of controversy and a few small uncontrolled studies, psilocybin and other hallucinogenic drugs are still illegal in most places. Political concerns often outweigh what doctors and patients think of these drugs.
“Psychedelics are currently banned in most countries, but the growing popularity of their therapeutic potential is leading many people to use them on their own without waiting for legal medical access,” says a recent study published in the Harm Reduction Journal. “Therapists therefore have an ethical duty to meet this need by providing support to clients using psychedelics.”
Reality runs faster
People have been consuming these “magic mushrooms” for thousands of years, and although current medical practice is to use opioids in the treatment of mental health, both the public and scientific researchers are discovering that the use of psilocybin can actually be safer.
“In the future, we plan to develop the most useful toolkit possible for both clinicians and researchers to create a new suite of psychedelics that marks a turning point for quality of life, reducing suffering and improving overall well-being”; says Nikzad.
